par Molinelli, Chiara;Jacobs, Flavia;Marta, Guilherme Nader;Borea, Roberto;Scavone, Graziana;Ottonello, Silvia;Fregatti, Piero;Villarreal-Garza, Cynthia;Bajpai, Jyoti;Kim, Hee Jeong;Puglisi, Silvia;de Azambuja, Evandro
;Lambertini, Matteo Md Phd M.
Référence Current Treatment Options in Oncology, 25, 4, page (523-542)
Publication Publié, 2024-04
![](/vufind/images/ULB/publications_list.png)
Référence Current Treatment Options in Oncology, 25, 4, page (523-542)
Publication Publié, 2024-04
Article révisé par les pairs
Résumé : | Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient’s comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients’ quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients’ quality of life. |